To Evaluate the Performance of HepaSphere Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy on Unresectable Colorectal Liver Metastases

Inclusion Criteria: * Age: ≥18 years old * Gender: no limitation * Histologically or cytologically documented advanced colorectal carcinoma with unresectable liver metastasis (existence of extrahepatic metastasis is acceptable) * Subjects must have at least one measurable lesion per RECIST v1.1 * Patients only received treatment with HepaSphere combined with hepatocellular arterial infusion chemotherapy (HAIC) as interventional therapy during the observation period * Child-Pugh: A-B * ECOG: 0-2. Exclusion Criteria: * Other malignant tumors in the past 5 years * Drug-eluting beads from other manufacturers were used during DEB-TACE * DEB-TACE combined with HAIC was used as postoperative adjuvant therapy * Pre- or post-surgery relevant examination results were unavailable * Imaging information for effectiveness evaluation was unavailable * Follow-up failure due to patient information errors, loss, refusal, etc